Christine Blank

The supply of fentanyl, epinephrine injection, and heparin, however, have been impacted by the July 19 tornado at Pfizer's North Carolina facility.

Beyfortus will be available ahead of the upcoming 2023-2024 RSV season. A price has not yet been set.

Most private health insurance plans are required to cover vaccines for COVID-19 without patient cost-sharing.

Medicare will cover Alzheimer’s drugs with full approval, including Leqembi — if the physician and patient participate in a real-world registry trial to gather additional data.

Elevidys is a one-time therapy that delivers to muscle a gene that codes for a shortened, functional form of dystrophin, which is mutated in Duchenne muscular dystrophy.

Jardiance and Synjardy are the first SGLT2 inhibitors approved for children with type 2 diabetes.

The supply interruption is the result of a combination of factors, including significant increases in demand, an increase in syphilis infection rates, as well as competitive shortages.

If approved, nirsevimab would be the first immunization specifically to protect infants through their first RSV season. The Prescription Drug User Fee Act date is in the third quarter of 2023.

The FDA has received adverse event reports after patients have used compounded semaglutide that contains salt formulations, which are different active ingredients than that used in the agency-approved drugs for diabetes and weight loss.

The combination of Lynparza and abiraterone reduced the risk of disease progression or death by 76% vs. abiraterone alone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

The Cyltezo Pen is scheduled to be on the market and available on July 1.

The compulsory orders will require the GPOs, which negotiate drug rebates on behalf of other PBMs, to provide information and records on their business practices.

The National Community Pharmacists Association now has plenty of allies in its fight with the pharmacy benefit managers.

A wholesale acquisition cost (WAC) for Elfabrio will be announced once it is available in a few weeks.

Treatment will benefit millions”of patients, says Eyenovia, the company that developed the product.

Despite having a highly differentiated clinical value proposition compared to branded, twice-nightly oxybates, Avadel is pricing Lumryz at $64.67 per gram or around $177,034 annually, which is on par with twice-nightly oxybate products that require chronic, middle-of-the-night awakening.

The American Hospital Association said the health insurers' report on drug prices, which highlights the higher prices charged by hospitals, is “a blatant attempt to deflect from the obvious — insurance companies continue to raise premiums for their enrollees and employer clients while pocketing billions in profit.”

Qulipta (atogepant) produced $158 million last year in net revenues in the U.S. as a preventive agent for episodic migraines.

Other indications for the blockbuster cancer mediation are not affected.

State officials say the new NYRx program will mean fewer restrictions and create a largest pharmacy network in the state.

A bipartisan Senate bill, Affordable Insulin Now Act of 2023, would require plans to cover insulin for no more than $35 per month.

Emergent BioSolutions hasn’t provided a price for the nonprescription Narcan but said the product will be available by late summer.

Rezzayo is a novel once-weekly antifungal approved to treat invasive candidiasis, a serious infection that can affect the blood, heart and brain.

CalRx will work with Civica to provide the most commonly used short- and long-acting insulins at planned prices of no more than $30 a vial and $55 for a box of five pre-filled pens.

The lower prices will take effect on Jan. 1, 2024, on both pre-filled pens and vials of basal, bolus and pre-mix insulins, including Levemir, Novolin, NovoLog and NovoLog Mix 70/30.

Daybue will be available by the end of April with a list price of about $375,000 annually.

Other news includes the launches of the first generic of an ulcer drug, the antipsychotic lurasidone, an extended-release version of topiramate for migraine, and additional strengths of the cancer drug lenalidomide. Additionally, Glenmark will distribute Cediprof's generic Adderall, and the FDA has accepted Amneal’s application for a generic naloxone nasal spray.

If approved, berdazimer could be the first prescription product treat molluscum, a common skin infection caused by poxvirus. The Prescription Drug User Fee Act goal date is Jan. 5, 2024.

Shigella cause an estimated 450,000 infections in the United States each year and an estimated $93 million in direct medical costs.

The companies have also submitted an EUA for a fourth dose of the bivalent COVID-19 vaccine in children 6 months through 4 years of age.